What Makes Crispr Therapeutics Ag (CRSP) a Good Buy?

Mon, Aug 18, 2025, 9:03 AM 3 min read

RGA Investment Advisors, an investment management company, has released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The second quarter-end figures concealed the inherent volatility in the market, which began with a steep sell-off and ended with clarity around global trade that changed the environment for evaluating enterprises. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025.

In its second-quarter 2025 investor letter, RGA Investment Advisors highlighted stocks such as CRISPR Therapeutics AG (NASDAQ:CRSP). CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene editing company. The one-month return of CRISPR Therapeutics AG (NASDAQ:CRSP) was -8.57%, and its shares gained 19.87% of their value over the last 52 weeks. On August 15, 2025, CRISPR Therapeutics AG (NASDAQ:CRSP) stock closed at $59.73 per share, with a market capitalization of $5.432 billion.

RGA Investment Advisors stated the following regarding CRISPR Therapeutics AG (NASDAQ:CRSP) in its second quarter 2025 investor letter:

"After commercial approval of Casgevy, CRISPR Therapeutics AG (NASDAQ:CRSP) shares traded over $90. At their worst in the April crash, shares changed hands at $30, a 2/3rd discount to their post-approval peak. The trade war would ultimately have a negligible impact on CRSP, but shares dropped nearly 30% in the Spring collapse. This made little sense to us, especially given the substantial cash balance the company has built with prudent financings along the way.